DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Andrew Malloy spent a career on Wall Street and also happens to be part of a 3rd generation family office created because of his...
Saralyn Mark, MD, a world renowned leader in women’s health, is an endocrinologist, geriatrician and women’s health specialist. She was the first Senior Medical...
With Sage’s AI Driven Medical Coding, Billing and Dictation, practitioners are eliminating the costly overhead of a medical coder while increasing productivity by 20%....
